- Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia - RecruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
For: Advanced Cancer · Metastatic Cancer · Ovarian CancerUnited States · France · Spain - Active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Brazil · Canada - Active not recruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study compares a new treatment called Sacituzumab Tirumotecan with standard care for recurrent or metastatic cervical cancer. It aims to see if the new treatment improves how long people live when current treatments aren't enough.
For: Cervical CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
This study is for people with advanced bowel cancer where previous chemotherapy hasn't worked. It compares a new drug called amivantamab, plus standard FOLFIRI chemotherapy, against other established treatments (cetuximab or bevacizumab) with FOLFIRI, to see which works best.
For: Colorectal NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
For: Metastatic Pancreatic Ductal Adenocarcinoma · PDACUnited States · Australia · Israel - Ongoing, recruitingPhase II and Phase III (Integrated)
Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritoneal recurrence - a multicentre randomized trial.
This study is looking at a new way to treat advanced stomach cancer that has a high chance of coming back in the tummy area. It tests a chemotherapy drug called Irinotecan, given into the tummy during surgery, to see if it can help prevent the cancer from returning and improve quality of life.
For: Gastric CarcinomaPoland - RecruitingPHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.
For: Neoplasms · Child · AdolescentUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This study is for cancer patients who are already taking part in another study using the drug adagrasib. It allows them to continue getting treatment if it's helping. It looks at how well adagrasib works long-term for various solid tumours, alone or with other cancer medicines.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
For: Gastric Cancer · Gastroesophageal Junction Cancer · Biliary Tract CancerUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
This study is testing a new drug, amivantamab, for advanced bowel cancer. It checks how well it works alone or with standard chemotherapy, and how safe it is. The study aims to find better ways to treat advanced bowel cancer.
For: Advanced or Metastatic Colorectal CancerUnited States · Belgium · Canada - Active not recruitingPHASE2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This study is testing a new drug, futibatinib, alongside standard cancer treatments for people with advanced oesophageal or pancreatic cancer. We want to see if this new combination helps fight the cancer and how safe it is.
For: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer · Esophageal Adenocarcinoma · Esophageal Squamous Cell CancerUnited States · France · Germany - Active not recruitingPHASE2
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
This study looks at a new drug, palbociclib, combined with standard chemotherapy for children, teenagers, and young adults with certain cancers that have come back or are hard to treat. It aims to find a safe dose and see how well it works.
For: Ewing Sarcoma · Solid Tumors · Rhabdoid TumorUnited States · Brazil · Canada - RecruitingPHASE3
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
This study is looking at a new way to treat bowel cancer that has spread only to the liver. It combines standard chemotherapy with newer targeted drugs, and a special way of delivering chemotherapy directly to the liver, to see if it works better.
For: Colorectal NeoplasmsBelgium · France - Active not recruitingPHASE3
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
This study is testing a new combination of two drugs, Regorafenib and Irinotecan, for people with advanced bowel cancer. It's comparing this new combination to Regorafenib on its own, to see if the combination works better when standard treatments are no longer effective.
For: Metastatic Colorectal Cancer (mCRC)France - Active not recruitingPHASE1
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
This study is testing a new drug, HRO761, for cancers that have specific DNA changes called MSI-high or dMMR. It aims to find a safe and effective dose of HRO761, alone or with other cancer medicines, and see how well it treats these cancers.
For: MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal CancersUnited States · Belgium · China - RecruitingPHASE1
A Study of ASP3082 in Adults With Advanced Solid Tumors
This study looks at a new drug, ASP3082, for adults with advanced solid cancers that have a specific genetic change called KRAS G12D. It checks how safe the drug is and what dose works best, sometimes with another drug called cetuximab.
For: Solid TumorUnited States · China · France - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study looks at a new medicine, sacituzumab tirumotecan, for advanced stomach or oesophagus cancer. It compares this new medicine to standard treatments to see if it's safer and works better for patients who have already had other treatments.
For: Gastroesophageal CancerUnited States · Belgium · Brazil - Active not recruitingPHASE2
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
This study looks at combining existing treatments for high-risk neuroblastoma to see if it works better. It's for children and young people who have already had intensive therapy, to help prevent the cancer from coming back.
For: Ganglioneuroblastoma, Nodular · NeuroblastomaUnited States · Australia · Canada - Active not recruitingPHASE3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This study is looking for a new treatment for pancreatic cancer that has spread. It compares a new medicine called RMC-6236 with standard chemotherapy for people whose cancer has already been treated once before. The aim is to see if the new medicine is safer and works better.
For: Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal AdenocarcinomaUnited States · France · Germany - Not yet recruitingPHASE3
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
This study looks at new ways to choose chemotherapy after pancreatic cancer surgery to prevent it from returning. Researchers are comparing standard methods with a new genetic test to see which works best for patients in the UK.
For: Pancreatic Ductal AdenocarcinomaGermany · Sweden - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
For: RhabdomyosarcomaAustralia · Austria · Belgium - RecruitingPHASE3
The Sagittarius Trial
This study looks at new ways to treat colon cancer after surgery to stop it coming back. It uses advanced tests called 'liquid biopsies' to help doctors choose the best treatment for each person, aiming for better results and fewer side effects.
For: Colon Cancer Stage II · Colon Cancer Stage IIIGermany · Italy · Spain - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - Not yet recruitingPHASE2
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
This study is looking at a new treatment for advanced bowel cancer that has spread. It combines standard chemotherapy with a new drug called Fruquintinib, comparing it to standard chemotherapy plus another drug, Bevacizumab.
For: Metastatic Colorectal Carcinoma (mCRC)France - RecruitingPHASE1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This early-stage study is testing a new drug, INBRX-109, for people with advanced solid tumours, including certain types of Ewing sarcoma and bowel cancer. Researchers want to see if it's safe and how well it works, both alone and with standard treatments. This is for patients who haven't responded to previous therapies.
For: Ewing Sarcoma · Colorectal AdenocarcinomaUnited States · France · Italy